博迅生物
(920504)
| 流通市值：0.00万 | | | 总市值：0.00万 |
| 流通股本：0.00万 | | | 总股本：0.00万 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 52,515,393.67 | 23,152,939.5 | 122,161,362.98 | 84,213,151.32 |
| 营业收入 | 52,515,393.67 | 23,152,939.5 | 122,161,362.98 | 84,213,151.32 |
| 二、营业总成本 | 47,789,310.23 | 20,703,452.66 | 109,497,810.76 | 77,306,703.9 |
| 营业成本 | 31,196,826.83 | 12,642,845.9 | 72,996,889.39 | 50,665,299.57 |
| 税金及附加 | 381,688.93 | 135,292.92 | 1,038,254.36 | 679,449.6 |
| 销售费用 | 4,846,144.68 | 2,126,718.39 | 11,620,319.46 | 8,962,364.72 |
| 管理费用 | 8,666,753.85 | 4,443,799.22 | 17,054,353.65 | 12,329,994.04 |
| 研发费用 | 2,704,449.44 | 1,332,779.7 | 6,781,632.54 | 4,685,125.05 |
| 财务费用 | -6,553.5 | 22,016.53 | 6,361.36 | -15,529.08 |
| 其中:利息费用 | 339,729.62 | 184,601.74 | 1,238,220.66 | 334,471.08 |
| 其中:利息收入 | 368,653.1 | 180,255.94 | 1,303,756.81 | 419,121.55 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 128,541.11 | 100,313.25 | 122,431.53 | 94,605.95 |
| 加:投资收益 | 596,677.54 | 217,166.56 | 1,948,153.09 | 1,142,545.97 |
| 资产处置收益 | 9,124.34 | - | - | - |
| 资产减值损失(新) | -1,602,597.21 | -923,935.07 | -835,520.27 | -634,223.12 |
| 信用减值损失(新) | -1,037,722.44 | -797,331.87 | 47,021.77 | -1,000,828.26 |
| 其他收益 | 1,372,572.26 | 400,430.31 | 4,424,507.93 | 3,048,693.74 |
| 四、营业利润 | 4,192,679.04 | 1,446,130.02 | 18,370,146.27 | 9,557,241.7 |
| 加:营业外收入 | 77,539.56 | 17,539.56 | 224,344.76 | 33,194.32 |
| 减:营业外支出 | 332,486.4 | 2,739.79 | 482,498.92 | 425,607.82 |
| 五、利润总额 | 3,937,732.2 | 1,460,929.79 | 18,111,992.11 | 9,164,828.2 |
| 减:所得税费用 | 301,346.38 | 221,281.46 | 2,301,550.69 | 988,934.75 |
| 六、净利润 | 3,636,385.82 | 1,239,648.33 | 15,810,441.42 | 8,175,893.45 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 3,636,385.82 | 1,239,648.33 | 15,810,441.42 | 8,175,893.45 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 3,636,385.82 | 1,239,648.33 | 15,810,441.42 | 8,175,893.45 |
| 扣除非经常损益后的净利润 | 2,947,724.47 | 859,378.85 | 13,682,901.37 | 7,039,990.77 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.08 | 0.03 | 0.36 | 0.19 |
| (二)稀释每股收益 | 0.08 | 0.03 | 0.36 | 0.19 |
| 九、综合收益总额 | 3,636,385.82 | 1,239,648.33 | 15,810,441.42 | 8,175,893.45 |
| 归属于母公司股东的综合收益总额 | 3,636,385.82 | 1,239,648.33 | 15,810,441.42 | 8,175,893.45 |
| 公告日期 | 2025-08-27 | 2025-04-28 | 2025-04-07 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |